New hope for tough leukemia: experimental drug CT0991 enters human testing
NCT ID NCT06709131
First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 21 times
Summary
This early-stage study tests a new drug called CT0991 in about 24 adults with acute myeloid leukemia that has come back or not responded to standard treatment. The main goals are to check the drug's safety, find the right dose, and see if it can help control the disease. Participants must be between 18 and 75 years old and expected to live more than 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.